MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Combined PET/CT Scanning Can Change the Management of High-Risk Cancers

By MedImaging International staff writers
Posted on 14 Dec 2015
Print article
The results of a new study show that PET/CT and whole body MRI scanning can be used to change the management of high-risk breast and prostate cancer patients.

The study was published in the December 2015, issue of the Journal of Nuclear Medicine and indicated that Positron Emission Tomography/Computed Tomography (PET/CT) and whole-body Magnetic Resonance Imaging (MRI) could detect extra-skeletal disease and change the management of high-risk breast and prostate cancer patients. The administration of F-18 sodium fluoride (NaF) and F-18 fluorodeoxyglucose (FDG) in a single PET/CT scan also provided significantly higher accuracy, and sensitivity for the detection of skeletal lesions.

The study group consisted of patients with breast or prostate cancers and compared results of the combined use of F-18 NaF/F-18 FDG PET/CT, to those obtained with Tc-99m MDP Bone Scintigraphy (BS) and Whole-Body MRI (WBMRI). The study included 15 women with breast cancer, and 15 men with prostate cancer that had been referred for standard of care BS and subsequently underwent NaF/FDG PET/CT and WBMRI. According to the results of the preliminary study NaF/FDG PET/CT was significantly more accurate in detecting skeletal lesions than WBMRI and Tc-99m MDP scintigraphy, and NaF/FDG PET/CT and WBMRI were able to detect extra-skeletal disease, and could change the way high-risk breast and prostate cancer patients treatment are managed.

Corresponding author of the study Andrei H. Iagaru, MD, FACNM, co-chief of the Stanford University (Stanford, CA, USA) division of Nuclear Medicine and Molecular Imaging, and co-director of the PET-MRI research program, said, "Using results from previous studies, this project attempts to identify the most appropriate approach for identifying lesions in selected breast and prostate cancer patients who are at high risk of developing metastatic disease. More work remains to be done, and our group is now exploring the use of combined NaF/FDG injections with state of the art PET/MRI technology for significant decreases in radiation exposure and improved diagnostic performance in accurately evaluating extent of disease in cancer patients.”

Related Links:

Stanford University


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Thyroid Shield
Standard Thyroid Shield
New
Ultrasound Table
Powered Ultrasound Table-Flat Top
Ultrasound System
Acclarix AX9

Print article

Channels

Ultrasound

view channel
Image: CAM figures of testing images (Photo courtesy of SPJ; DOI:10.34133/research.0319)

Diagnostic System Automatically Analyzes TTE Images to Identify Congenital Heart Disease

Congenital heart disease (CHD) is one of the most prevalent congenital anomalies worldwide, presenting substantial health and financial challenges for affected patients. Early detection and treatment of... Read more

Nuclear Medicine

view channel
Image: Researchers have identified a new imaging biomarker for tumor responses to ICB therapy (Photo courtesy of 123RF)

New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy

Immunotherapies, such as immune checkpoint blockade (ICB), have shown promising clinical results in treating melanoma, non-small cell lung cancer, and other tumor types. However, the effectiveness of these... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more